D&D Pharmatech Co., Ltd. 347850
KRX · South Korea · Health Technology
KRW 43,950.00-1,300.00 (-2.87%)
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The obesity therapeutics market is becoming increasingly concentrated around an Eli Lilly–Novo Nordisk duopoly, with tirzepatide (ZEPBOUND) and semaglutide (WEGOVY) continuing to dominate the US branded treatment landscape. However, the competitive environment is evolving rapidly with the introduction of oral GLP-1 therapies. Novo Nordisk's oral WEGOVY surpassed 5 million cumulative US prescriptions within 30 weeks, while Eli Lilly's FOUNDAYO gained notable momentum among patients initiating ora
GYEONGGI-DO, South Korea & GAITHERSBURG, Md., July 21, 2026--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced the publication of 12-week results from its Phase 2 DD01-DN-2 study evaluating zabopegdutide (DD01) in patients with MASLD/MASH in the Lancet Gastroenterology & Hepatology.
HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 clinical trial of zabopegdutide (DD01) - an investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH).
LG AI Research announced today that it has signed a master agreement for a joint next-generation oral peptide drug development project with D&D Pharmatech at the LG Twin Towers in Yeouido, Seoul.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.